Table 4 Occurrence of fatal and non-fatal CVD events during follow up according to sero-prevalence of Chlamydia pneumoniae (CP), chlamydia heat shock protein (ch-hsp)60, human heat shock protein (h-hsp)60 and diabetes (DM)
N (Column%) | Fatal and Non-Fatal CVD-Events During Follow-up N (column %) | P-value a | |
|---|---|---|---|
CP – (IgA) (N = 1030) | |||
negative | 645 (62.6) | 37 (5.7) | |
positive | 385 (37.4) | 34 (8.8) | 0.04 |
Patients with DM (N = 199) | |||
CP – (IgA)-negative | 111 (55.8) | 12 (10.8) | |
CP – (IgA)-positive | 88 (44.2) | 12 (13.6) | 0.5 |
CP – (IgG) | |||
negative | 625 (60.7) | 37 (5.9) | |
positive | 405 (39.3) | 34 (8.4) | 0.1 |
Patients with DM (N = 199) | |||
CP – (IgG)-negative | 114 (57.3) | 12 (10.5) | |
CP – (IgG)-positive | 85 (42.7) | 12 (14.1) | 0.4 |
Ch-hsp60 | |||
negative | 801 (77.8) | 54 (6.7) | |
positive | 228 (22.2) | 17 (7.5) | 0.7 |
Patients with DM (N = 199) | |||
Ch-hsp60-negative | 158 (79.4) | 18 (11.4) | |
Ch-hsp60-positive | 41 (20.6) | 6 (14.6) | 0.6 |
h-hsp60 (N = 983) b | |||
negative | 900 (91.6) | 64 (7.1) | |
positive | 83 (8.4) | 4 (4.8) | 0.4 |
Patients with DM (N = 199) | |||
h-hsp60-negative | 186 (93.5) | 21 (11.3) | |
h-hsp60-positive | 13 (6.5) | 3 (23.1) | 0.2 |